A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study

Exclusion Criteria

• •Pregnancy or lactating women
• •Known prior or current diagnosis of other types of malignancies comorbidities
• •Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen
• •Recipients of organ transplant or prior bone marrow transplant or stem cell transplant
• •Recipients of blood transfusion within 30 days prior to screen
• •Recipients of therapy in past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide
• •Unsuitable for this trial determined by the researchers
• •Low-quality samples: images only partially showing the lungs or in lateral decubitus position, unreadable due to severe motion artifacts/metal artifacts, or with missing critical metadata
• •Pregnancy or lactating women
• •Known prior or current diagnosis of other types of malignancies comorbidities
• •Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen
• •Recipients of organ transplant or prior bone marrow transplant or stem cell transplant
• •Recipients of blood transfusion within 30 days prior to screen
• •Recipients of therapy in the past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide
• •Unsuitable for this trial determined by the researchers
• •Low-quality samples: images only partially showing the lungs or in lateral decubitus position, unreadable due to severe motion artifacts/metal artifacts, or with missing critical metadata